Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study.
Small cell lung cancer (SCLC)
amrubicin
etoposide
irinotecan
topoisomerase inhibitor
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
28
02
2022
accepted:
11
07
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
ppublish
Résumé
Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors. This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institutions in Japan between April 2015 and November 2020. The progression-free survival of amrubicin monotherapy was investigated using the Kaplan-Meier method. A total of 320 patients were enrolled in this study, with 59 (18%) receiving platinum plus topoisomerase I inhibitor irinotecan and 261 (82%) receiving platinum plus topoisomerase II inhibitor etoposide as first-line treatment. The progression-free survival of amrubicin was significantly longer in the irinotecan group than in the etoposide group (3.2 These results showed that different types of topoisomerase inhibitors could affect the efficacy of amrubicin monotherapy in the second-line treatment of patients with relapsed ES-SCLC.
Sections du résumé
Background
UNASSIGNED
Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors.
Methods
UNASSIGNED
This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institutions in Japan between April 2015 and November 2020. The progression-free survival of amrubicin monotherapy was investigated using the Kaplan-Meier method.
Results
UNASSIGNED
A total of 320 patients were enrolled in this study, with 59 (18%) receiving platinum plus topoisomerase I inhibitor irinotecan and 261 (82%) receiving platinum plus topoisomerase II inhibitor etoposide as first-line treatment. The progression-free survival of amrubicin was significantly longer in the irinotecan group than in the etoposide group (3.2
Conclusions
UNASSIGNED
These results showed that different types of topoisomerase inhibitors could affect the efficacy of amrubicin monotherapy in the second-line treatment of patients with relapsed ES-SCLC.
Identifiants
pubmed: 36248326
doi: 10.21037/tlcr-22-160
pii: tlcr-11-09-1847
pmc: PMC9554692
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1847-1857Informations de copyright
2022 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-160/coif). Tadaaki Yamada serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023. Tadaaki Yamada received commercial research grants from Pfizer, Ono Pharmaceutical, Janssen Pharmaceutical K.K., and Takeda Pharmaceutical Company Limited and personal fees from Eli Lilly. AO received personal fees from Chugai-Roche, AstraZeneca, Boehringer Ingelheim, and Bristol Myers Squibb. KT received research grants from Chugai-Roche and Ono Pharmaceutical and individual fees from AstraZeneca, Chugai-Roche, MSD-Merck, Eli Lilly Boehringer Ingelheim, and Daiichi Sankyo. The other authors have no conflicts of interest to declare.
Références
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Natl Cancer Inst. 1989 Nov 15;81(22):1732-5
pubmed: 2553992
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer Res. 1988 Nov 15;48(22):6404-10
pubmed: 2846151
N Engl J Med. 2002 Jan 10;346(2):85-91
pubmed: 11784874
Invest New Drugs. 2007 Oct;25(5):499-504
pubmed: 17628745
J Thorac Oncol. 2018 Sep;13(9):1393-1399
pubmed: 29775808
Clin Transl Oncol. 2020 Feb;22(2):245-255
pubmed: 32040815
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cancer. 2015 Mar 1;121(5):664-72
pubmed: 25336398
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
Lung Cancer. 2014 Apr;84(1):67-72
pubmed: 24530204
J Clin Oncol. 2014 Dec 10;32(35):4012-9
pubmed: 25385727
Cancer Res. 1990 Dec 15;50(24):7962-5
pubmed: 2174738
Cancer Res Treat. 2019 Jan;51(1):119-127
pubmed: 29529858
Ann Oncol. 2010 Sep;21(9):1810-1816
pubmed: 20231298
Cancer Biol Ther. 2006 Dec;5(12):1600-7
pubmed: 17224634
Lancet Oncol. 2021 Jan;22(1):51-65
pubmed: 33285097
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Sci Rep. 2016 Jan 11;6:18999
pubmed: 26750506
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Clin Oncol. 2016 Nov 1;34(31):3740-3748
pubmed: 27458307